{"id":2869,"date":"2018-10-31T15:19:26","date_gmt":"2018-10-31T15:19:26","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=2869"},"modified":"2018-10-31T15:24:02","modified_gmt":"2018-10-31T15:24:02","slug":"presentation-du-poster-en-collaboration-avec-novadiscovery-a-licsb-2018","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/presentation-du-poster-en-collaboration-avec-novadiscovery-a-licsb-2018\/","title":{"rendered":"Pr\u00e9sentation du Poster en collaboration avec Novadiscovery \u00e0 l&#8217;ICSB 2018"},"content":{"rendered":"<p>Â鶹Æƽâ°æ est fier de collaborer avec <a href=\"https:\/\/www.novadiscovery.com\/\">Novadiscovery<\/a>qui pr\u00e9sente aujourd\u2019hui un poster \u00e0 l\u2019ISCB  intitul\u00e9 \u00ab une approche de mod\u00e9lisation logique pour pr\u00e9parer et acc\u00e9l\u00e9rer le design des mod\u00e8les ODE : Application  m\u00e9tabolisme des acides biliaires \u00bb. Le mod\u00e8le du m\u00e9tabolisme des acides biliaires a \u00e9t\u00e9 d\u00e9velopp\u00e9 dans le contexte d\u2019un projet avec Â鶹Æƽâ°æ, dont l\u2019objectif \u00e9tait de mod\u00e9liser le virus de l\u2019h\u00e9patite B chronique et de la st\u00e9atose non-alcoolique (NASH).<br \/>\n <a href=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2018\/10\/ICSB-2018-Poster-ENYO-Pharma-Novadiscovery-MOD7.pdf\" target=\"_blank\" class=\"tano-file\"><span class=\"tano_download_icon\"><\/span><span class=\"tano_file_title\">Poster with Novadiscovery<\/span><\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Â鶹Æƽâ°æ est fier de collaborer avec <a href=\"https:\/\/www.novadiscovery.com\/\">Novadiscovery<\/a>qui pr\u00e9sente aujourd\u2019hui un poster \u00e0 l\u2019ISCB  intitul\u00e9 \u00ab une approche de mod\u00e9lisation logique pour pr\u00e9parer et acc\u00e9l\u00e9rer le design des mod\u00e8les ODE : Application  m\u00e9tabolisme des acides biliaires \u00bb. Le mod\u00e8le du m\u00e9tabolisme des acides biliaires a \u00e9t\u00e9 d\u00e9velopp\u00e9 dans le contexte d\u2019un projet avec Â鶹Æƽâ°æ, dont l\u2019objectif \u00e9tait de mod\u00e9liser le virus de l\u2019h\u00e9patite B chronique et de la st\u00e9atose non-alcoolique (NASH).<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/presentation-du-poster-en-collaboration-avec-novadiscovery-a-licsb-2018\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[21],"tags":[],"class_list":["post-2869","post","type-post","status-publish","format-standard","hentry","category-latest-news-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/latest-news-fr\/\" rel=\"category tag\">Br\u00e8ves<\/a>","rttpg_excerpt":"Â鶹Æƽâ°æ est fier de collaborer avec Novadiscoveryqui pr\u00e9sente aujourd\u2019hui un poster \u00e0 l\u2019ISCB intitul\u00e9 \u00ab une approche de mod\u00e9lisation logique pour pr\u00e9parer et acc\u00e9l\u00e9rer le design des mod\u00e8les ODE : Application m\u00e9tabolisme des acides biliaires \u00bb. Le mod\u00e8le du m\u00e9tabolisme des acides biliaires a \u00e9t\u00e9 d\u00e9velopp\u00e9 dans le contexte d\u2019un projet avec Â鶹Æƽâ°æ,&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/2869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=2869"}],"version-history":[{"count":4,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/2869\/revisions"}],"predecessor-version":[{"id":2875,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/2869\/revisions\/2875"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=2869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=2869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=2869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}